Most lifeforms on Earth are made up of natural DNA. However, scientists are now much closer to creating artificial creatures using synthetic methods. They did this by basically making additions to DNA in ways that nature has yet to achieve. By doing so, the researchers are able to provide the organism certain traits that their natural counterparts do not have.
This isn’t the first time that the researchers from Scripps Research Institute in La Jolla, California have managed to progress in creating synthetic life. Their latest study was published in Nature, explaining how far the scientists have managed to go this time. It would seem that the semi-synthetic E. coli that they managed to create are now able to express proteins it wasn’t able to before.
“The results demonstrate that interactions other than hydrogen bonding can contribute to every step of information storage and retrieval. The resulting semi-synthetic organism both encodes and retrieves increased information and should serve as a platform for the creation of new life forms and functions,” the study’s Abstract reads.
Project head chemical biologist Floyd Romesberg also spoke to Reuters recently and explained exactly how significant this development is. By adding X and Y to the E. coli DNA, the researchers rewrote something that’s been part of the natural order since the dawn of time.
“This is the first time ever a cell has translated a protein using something other than G, C, A or T,” Romesberg said.
For those who might be concerned that this could lead to a catastrophic explosion of new synthetic life-forms, Romesberg assures that this is not impossible. He and his team have no intention to create a hybrid species and then let them propagate. More to the point, the semi-synthetic organisms can’t bond with natural DNA and they would not be able to survive anywhere other than a laboratory setting.


Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
Tabletop particle accelerator could transform medicine and materials science
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
Neuralink Expands Brain Implant Trials with 12 Global Patients
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 



